Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of the PI3K Inhibitor TL117 Alone and in Combination With Paclitaxel in Patients With Relapsed/Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT04843098 is registered in ClinicalTrials.gov with Suzhou Junde Biotechnology Co., Ltd as lead sponsor.

NCT NCT04843098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04843098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of the PI3K Inhibitor TL117 Alone and in Combination With Paclitaxel in Patients With Relapsed/Metastatic Squamous Cell Carcinoma of the Head and Neck
Lead sponsor
Suzhou Junde Biotechnology Co., Ltd
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 26, 2021
Completion date
June 30, 2025
Enrollment
108 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma